Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

Leerink Partnrs dropped their Q2 2025 EPS estimates for Cencora in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.08 per ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Cencora (NYSE:COR – Get Free Report) had its price objective raised by equities research analysts at JPMorgan Chase & Co. from $289.00 to $301.00 in a report released on Friday,Benzinga reports.